Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neurotoxicity

Area of Science:

• Oncology
• Pharmacogenomics
• Clinical Pharmacology

Background:

• Pharmacogenomics aids in predicting individual treatment responses and adverse drug effects in oncology.
• Chemotherapy-induced peripheral neurotoxicity (CIPN) is a severe, potentially permanent side effect impacting patient quality of life (QoL).
• Current pharmacogenomics approaches for CIPN prediction have yielded limited success, necessitating methodological improvements.

Purpose of the Study:

• To investigate the reasons behind the limited effectiveness of pharmacogenomics in predicting CIPN.
• To propose a collaborative approach between "bench-side" pharmacogenomics and "bed-side" clinimetrics for enhanced genetic profiling in CIPN.

Main Methods:

• Review of existing pharmacogenomics strategies applied to CIPN.
• Analysis of the integration challenges between genetic data and clinical outcomes.
• Conceptual framework development for combining "bench-side" and "bed-side" data.

Main Results:

• The effectiveness of genetic analysis for CIPN is hampered by incorrect application and integration.
• A significant gap exists between "bench-side" genetic discoveries and "bed-side" clinical utility.
• Cooperation between pharmacogenomics and clinimetrics is essential for accurate genetic profiling.

Conclusions:

• Methodological improvements are required to make pharmacogenomics effective for CIPN prediction.
• Integrating clinimetrics with pharmacogenomics can enhance the clinical utility of genetic profiling.
• A combined approach is vital for personalizing cancer therapy and mitigating CIPN, thereby improving QoL.